Hai Wu

Shanghai Junshi Biosciences Co., LTD

Shanghai

China

SCHOLARLY PAPERS

2

DOWNLOADS

50

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (2)

1.

Axitinib in Combination with Toripalimab, a Humanized IgG4 mAb Against Programmed Death-1 (PD-1) in Patients with Metastatic Mucosal Melanoma: A Non-Randomized, Open-Label, Dose-Finding, and Cohort-Expansion Phase 1b Trial

Number of pages: 148 Posted: 24 Jan 2019
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, OrigiMed, Inc., Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Harvard University - Harvard Medical School and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads 36 (470,265)

Abstract:

Loading...

Mucosal, Melanoma, anti-PD-1 antibody, Axitinib

2.

Safety, Efficacy and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial

Number of pages: 139 Posted: 26 Nov 2019
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Harbin Medical University - Cancer Hospital, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, OrigiMed, Inc., Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD and Peking University - Department of Gastrointestinal Oncology
Downloads 14 (595,233)

Abstract:

Loading...

Neuroendocrine neoplasm, NET, NEC, PD-1,toripalimab